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Introduction: Female sex is predictive of poor functional outcome in stroke, even 
after correction for prognostic factors. Poor quality of life (QoL) is observed in stroke 
survivors, with lower scores seen in the most disabled patients. We used data from 
the TAIST trial to assess the relationship between sex and QoL after ischaemic stroke. 
 
Methods: TAIST was a randomised controlled trial assessing the safety and efficacy 
of tinzaparin versus aspirin in 1,484 patients with acute ischaemic stroke. QoL was 
measured at 180 days post randomisation using the short-form 36 health survey 
which assesses QoL across eight domains. The relationship between sex and each 
domain was assessed using ordinal regression, both unadjusted and adjusted for key 
prognostics factors. 
 
Results: Of the 1,484 patients randomised into TAIST, 216 had died at 180 days post 
randomisation. 1,268 survivors were included in this analysis, 694 males (55%), 574 
females (45%). Females tended to score lower than males across all QoL domains 
(apart from general health); statistically significant lower scores were seen for 
physical functioning (odds ratio (OR) 0.58, 95% confidence interval (CI) 0.47-0.72), 
vitality (OR 0.79, 95% CI 0.64-0.98) and mental health (OR 0.75, 95% CI 0.61-0.93). 
The results for physical functioning and mental health remained significant after 
adjustment for prognostic variables (OR 0.73, 95% CI 0.58-0.92; OR 0.76, 95% CI 
0.60-0.95 respectively).  
 
Conclusions: QoL, in particular physical function and mental health domains, is lower 
in female patients after stroke. This difference persists even after correction for known 




Quality of life (QoL) is widely recognised to be impaired after stroke 1, 2 and is related 
to post-stroke disability and handicap.3 It is clear that both motor and non-motor 
symptoms play an important role in recovery after stroke.4 As such, there is an 
increasing call for trials to monitor QoL in addition to other measures such as modified 
Rankin scale and Barthel Index in order to give a broader assessment of outcome 
after stroke.3 
 
Outcome in female stroke patients has been reported to be worse than in males, with 
an increased risk of dependency and institutionalisation.5-7 However, female stroke 
patients tend to be older and more frail, which accounts for some of the worse 
prognosis. The relationship between QoL and sex is unclear; whilst some studies have 
observed lower QoL scores in females, 8-11 others have detected no sex difference.7 12-
14 
 
We sought to further assess the relationship between sex and QoL using data from the 





TAIST compared the safety and efficacy of tinzaparin (low molecular weight heparin) 
given at high dose (175 anti-Xa IU/kg/day), tinzaparin at medium dose (100 anti-Xa 
IU/kg/day), and aspirin (300 mg od) in patients with acute ischaemic stroke.15 
Subjects were included within 48 hours of stroke onset. All data were collected 
prospectively as part of the trial protocol.15 
 
Quality of life 
QoL was measured at 180 days after randomisation by a face to face interview 15 
using the short form 36 health survey,16 which assesses quality of life across eight 
domains: physical functioning; physical role; bodily pain; general health; vitality; 
social functioning; emotional role; and mental heath.16 We used the transposed 
versions for each domain, so each are scored from zero to 100 with zero relating to 
the worst state of QoL and 100 relating to the best state.16 Summary scores were also 
calculated for the four physical and four mental domains.17 All patients completed the 
assessment themselves and proxies were not used.  
 
Outcome 
Outcome was measured using the modified Rankin Scale and Barthel Index at 180 
days post randomisation.15 
 
Statistical methods 
Prognostic baseline factors were compared by sex using Fisher’s exact test for 
categorical data and the Wilcoxon test for ordinal or continuous data. The 
relationships between sex, QoL domains, functional outcome, and discharge 
4 
disposition were assessed using ordinal regression or logistic regression, both 
unadjusted and adjusted for 8 key prognostic factors: age, baseline systolic blood 
pressure, severity (Scandinavian Stroke Scale), pre morbid modified Rankin Scale, pre 
morbid residency, history of myocardial infarction, stroke type (cardioembolic, large 
artery), and treatment group. To compensate for the imbalance in age between the 
sexes two matched analyses were also performed: (i) individual males and females 
were paired for age (within 3 years) and severity (within 3 points); and (ii) on age 
and severity (as in i), previous MI and type of stroke (cardioembolic, large artery). All 
analyses were performed using SAS (SAS Institute, Cary, North Carolina, USA). 
Where missing data occurred patients were excluded. Significance was taken at 





Of the 1,484 patients randomised into TAIST, 216 had died at 180 days post 
randomisation: 113 males (14%) and 103 females (15%). Hence, 1,268 survivors 
were included in this analysis: 694 males (55%), 574 females (45%). The baseline 
characteristics of included patients by sex are shown in table 1. Many prognostic 
factors were similar by sex, although females were older, more likely to have atrial 
fibrillation, a stroke of cardioembolic types, have lower pre morbid functional status 
(modified Rankin Scale (mRS)), more likely to be in a nursing home, and were less 
likely to have suffered a previous myocardial infarctions or had a stroke of large artery 
type.  
 
Quality of Life 
Females had lower QoL scores than men, in particular relating to physical functioning, 
vitality, and mental health (table 2). When adjusted for key prognostic factors (age, 
baseline systolic blood pressure, Scandinavian Stroke Scale, history of myocardial 
infarction, stroke type, pre morbid mRS, residency and treatment group) the 
differences in physical functioning and mental health remained statistically significant, 
with females reporting scores that were around 25% lower than males (table 2). 
Physical and mental summary QoL scores did not differ by sex after adjustment. 
 
Outcome 
The modified Rankin scale differed significantly by sex with females having a worse 
functional outcome at 6 months (unadjusted p=0.001; adjusted p=0.26 (table 2, 
figure 1). Similarly, Barthel Index scores were lower in females (unadjusted 
p<0.0001, adjusted p=0.13) (table 2). A poor functional outcome (mRS) was 
6 
associated with lower physical (rs=-6.3, p<0.0001) and mental (rs=-0.2, p<0.0001) 
QoL domains. Mortality was similar between males and females (table 2). At 6 months 
post randomisation, more males than females were resident in their own home; 
conversely, more females than males were resident in a nursing home (table 2, figure 
2).  
 
Matching of data by sex 
Repeating the analysis on matched sub-sets of the TAIST data gave comparable 
results to the unmatched analysis (figure 3). The age and severity matched data and 
the age, severity, MI and stroke type matched data both showed that females had 
consistently worse QoL than males for all domains with statistically significant 
differences for physical functioning and mental health in both data sets, and 




The main finding in this study of patients with acute ischaemic stroke is that female 
patients have lower quality of life scores at 6 months than males, especially in the 
domains of physical function and mental health, and possibly vitality. Similar findings 
have been seen in earlier studies of QoL post stroke 8-11 as well as female patients 
with ischaemic heart disease.18 Earlier studies in stroke limited statistical adjustment 
to age 11 whereas we were able to correct for additional prognostic factors including 
severity and co morbidity. Furthermore, previous studies have assigned a score of 
zero to deceased patients,1 which may exaggerate lower scores in females since they 
have a trend to increased mortality (as seen here). However, our findings were not 
confounded in this manner as dead patients were excluded from this analysis. 
 
Despite demonstrating a relationship between sex and individual domain scores, we 
did not show any major relationship between summary scores and sex when adjusting 
for other prognostic factors. This is in keeping with previous work,19, 20 and is not 
surprising as the summation of domains can lead to the loss of data. At present there 
is little evidence to support the use of such summary scores.20 
 
Females also had a worse functional outcome, whether judged using the modified 
Rankin Scale or Barthel Index. These scales largely measure physical disability and 
dependency so it is unsurprising that the functional and physical QoL domains are 
interrelated and differ similarly by sex. 
 
One possible explanation for the gender difference may arise from a difference in 
coping and adaptation patterns. In other illnesses, marked gender differences can be 
discerned,21 and the role of coping and adaptive strategies in stroke is a newly 
8 
developed field of interest.22 Females have also been shown to report lower QoL in a 
general population.23 Another explanation for this difference may be the place of 
residence 6 months post stroke, with many more females being resident in a nursing 
home than males; QoL is likely to be less well rated in an institution than at home. 
 
This study has several limitations. First, the data come from a randomised controlled 
trial which excluded both very mild and very severe strokes. Excluding mild strokes 
will tend to cause a floor effect in QoL domains, well recognised when using the SF-
36.20 (Excluding patients with very severe strokes is less of a problem since many die 
and therefore would not contribute QoL data.) Second, QoL was assessed at only one 
time point (6 months post stroke) despite temporal trends being recognised in both 
physical and mental domains of QoL.1,2, 10 Third, depression and QoL are associated 
with each other with depressed patients have a lower QoL. Although female stroke 
patients have an increased prevalence of post stroke depression,8 we could not take 
account of this since TAIST did not collect the relevant information. Finally, although 
the SF-36 is one of the most widely used measures of quality of life, it may not meet 
the specific demands of measuring quality of life after stroke as well as other 
measures 24 and may not accord sufficient priority to the subjective priorities of stroke 
patients in what is important in their quality of life.25 Despite these limitations, these 
data come from a large high fidelity trial, and exhibit external validity.8-11 
 
In summary, female stroke patients have a lower quality of life, especially in the 
domains of physical and mental health, which is independent of age, stroke severity 
and aetiological type, and other co-morbid factors. Females also have a worse 
functional outcome. Since medicinal interventions such as aspirin and alteplase 
administration improve functional outcome, it will be important to determine if quality 
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